COMPANY DECLARES MARKET DOMINATION TRAJECTORY

TIANRONG MEDICAL GROUP INC. (OTCID:TNMD) FILES Q1 DISCLOSURE — COMPANY DECLARES MARKET DOMINATION TRAJECTORY; ELEUTHERA, BAHAMAS ASSET POSITIONING SET TO AMPLIFY NEXT QUARTER’S FINANCIALS

 Tianrong Medical Group Inc. (OTCID:TNMD) has filed its First Quarter Disclosure Statement with OTC Markets, and the results send a clear message to the market: TNMD is not competing — TNMD is positioning to dominate.

The company’s Q1 balance sheet reflects exceptional strength, the product of a deliberate, disciplined restructuring strategy designed to prepare TNMD for aggressive expansion. With the filing now live, TNMD confirmed that its next quarterly disclosure will include a major infusion of new assets, including developments tied to its strategic Eleuthera, Bahamas property, a location rapidly emerging as one of the company’s most powerful long‑term value drivers.

Curtis Philpot, CEO of TNMD, issued the following statement:

“TNMD is entering a market‑domination phase. Our Q1 filing shows a balance sheet built for scale, leverage, and acceleration. We’ve eliminated inefficiencies, fortified our core, and positioned ourselves to move with force. Next quarter, we’re not adding marginal improvements — we’re adding assets that shift the entire trajectory of this company.”

Philpot continued:

“Our Eleuthera, Bahamas position is a strategic weapon. It’s rare, it’s scarce, and it’s expanding. As these assets enter our financials, TNMD’s footprint will grow in a way the market cannot ignore. We are not signaling potential — we are demonstrating control.”

TNMD’s Q1 disclosure is now posted on OTC Markets, with additional updates scheduled as the company executes its expansion strategy and prepares for a materially stronger Q2.